Cargando…
The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
Co‐treatment with gastric acid suppressants (GAS) in patients taking anticancer drugs that exhibit pH‐dependant absorption may lead to decreased drug exposure and may hamper drug efficacy. In our study, we investigated whether a 1‐hour time interval between subsequent intake of pazopanib and GAS cou...
Autores principales: | Krens, Stefanie D., Lubberman, Floor J. E., van Egmond, Marthe, Jansman, Frank G. A., Burger, David M., Hamberg, Paul, Vervenne, Walter L., Gelderblom, Hans, van der Graaf, Winette T. A., Desar, Ingrid M. E., van Herpen, Carla M. L., van Erp, Nielka P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048885/ https://www.ncbi.nlm.nih.gov/pubmed/33428771 http://dx.doi.org/10.1002/ijc.33469 |
Ejemplares similares
-
Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021) -
Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020) -
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018) -
The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019) -
The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)